Cyclodextrins improving the physicochemical and pharmacological properties of antidepressant drugs: a patent review

References

• Singh P, Singh TG. Modulation of muscarinic system with serotonin-norepinephrine reuptake inhibitor antidepressant attenuates depression in mice. Indian J Pharmacol. 2015;47(4):388–393.
   PubMed Web of Science ®Google Scholar
• Carhart-Harris RL, Bolstridge M, Rucker J, et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry. 2016;3(7):619–627.
   PubMed Web of Science ®Google Scholar
• Meylana EM, Halfon O, Magistretti PJ, et al. The HDAC inhibitor SAHA improves depressive-like behavior of CRTC1-deficient mice: possible relevance for treatment-resistant depression. Neuropharmacology. 2016;107:111–121.
   PubMed Web of Science ®Google Scholar
• Scheggi S, Melis M, De Felice M, et al. PPARα modulation of mesolimbic dopamine transmission rescues depression-related behaviors. Neuropharmacology. 2016;110:251–259.
   PubMed Web of Science ®Google Scholar
• Fisar Z, Hroudová J, Raboch J. Inhibition of monoamine oxidase activity by antidepressants and mood stabilizers. Neuro Endocrinol Lett. 2010;31(5):645–656.
   PubMed Web of Science ®Google Scholar
• Galdino PM, De Oliveira DR, Florentino IF, et al. Involvement of the monoamine system in antidepressant-like properties of 4-(1-phenyl-1h-pyrazol-4-ylmethyl)-piperazine-1-carboxylic acid ethyl ester. Life Sci. 2015;143:187–193.
   PubMed Web of Science ®Google Scholar
• Zhen L, Zhu J, Zhao X, et al. The antidepressant-like effect of fisetin involves the serotonergic and noradrenergic system. Behav Brain Res. 2012;228(2):359–366.
   PubMed Web of Science ®Google Scholar
• Martinowich K, Manji H, Lu B. New insights into BDNF function in depression and anxiety. Nat Neurosci. 2007;10(9):1089–1093.
   PubMed Web of Science ®Google Scholar
• Castrén E, Rantamäki T. The role of BDNF and its receptors in depression and antidepressant drug action: reactivation of developmental plasticity. Dev Neurobiol. 2010;70(5):289–297.
   PubMed Web of Science ®Google Scholar
• Dixon Clarke SE, Ramsay RR. Dietary inhibitors of monoamine oxidase A. J Neural Transm. 2011;118(7):1031–1041.
   PubMed Web of Science ®Google Scholar
• Adongo DW, Kukuia KK, Mante PK, et al. Antidepressant-like effect of the leaves of pseudospondias microcarpa in mice: evidence for the involvement of the serotoninergic system, NMDA receptor complex, and nitric oxide pathway. Biomed Res Int. 2015;2015:397943.
   PubMedGoogle Scholar
• Amick HR, Gartlehner G, Gaynes BN, et al. Comparative benefits and harms of second generation antidepressants and cognitive behavioral therapies in initial treatment of major depressive disorder: systematic review and meta-analysis. Bmj. 2015;351:6019.
   PubMed Web of Science ®Google Scholar
• Krishnan V, Nestler EJ. The molecular neurobiology of depression. Nature. 2008;455(7215):894–902.
   PubMed Web of Science ®Google Scholar
• Girish C, Raj V, Arya J, et al. Evidence for the involvement of the monoaminergic system, but not the opioid system in the antidepressant-like activity of ellagic acid in mice. Eur J Pharmacol. 2012;682(1–3):118–125.
   PubMed Web of Science ®Google Scholar
• Kirby T. Ketamine for depression: the highs and lows. Lancet Psychiatry. 2015;2(9):783–784.
   PubMed Web of Science ®Google Scholar
• Gaynes BN. Identifying difficult-to-treat depression: differential diagnosis, subtypes, and comorbidities. J Clin Psychiatry. 2009;70:10–15.
   PubMed Web of Science ®Google Scholar
• Machado DG, Bettio LEB, Cunha MP, et al. Antidepressant-like effect of rutin isolated from the ethanolic extract from Schinus molle L. in mice: evidence for the involvement of the serotonergic and noradrenergic systems. Eur J Pharmacol. 2008;587(1–3):163–168.
   PubMed Web of Science ®Google Scholar
• Brunton LL, et al. As bases farmacológicas da terapêutica de Goodman e Gilman. Porto Alegre (BR): AMGH; 2012.
   Google Scholar
• Grosso C, Valentão P, Ferreres F, et al. The use of flavonoids in central nervous system disorders. Curr Med Chem. 2013;20(37):4694–4719.
   PubMed Web of Science ®Google Scholar
• Brito RG, Araújo AAS, Quintans JSS, et al. Enhanced analgesic activity by cyclodextrins - a systematic review and meta-analysis. Expert Opin Drug Deliv. 2015;12:1677–1688.
   PubMed Web of Science ®Google Scholar
• Santos PL, Brito RG, Quintans JS, et al. Cyclodextrins as encapsulation agents to improve the anti-inflammatory drugs profile: a systematic review and meta-analysis. Curr Pharm Des. 2017;23:1–12.
   PubMed Web of Science ®Google Scholar
• Lannoy A, Kania N, Bleta R, et al. Photocatalysis of volatile organic compounds in water: towards a deeper understanding of the role of cyclodextrins in the photodegradation of toluene over titanium dioxide. J Colloid Interface Sci. 2016;461:317–325.
   PubMed Web of Science ®Google Scholar
• Villiers A. Sur la fermentation de la fécule par l’action du ferment butyrique. C R Acad Sci. 1891;112:536–538.
   Google Scholar
• Loftsson T, Duchêne D. Cyclodextrins and their pharmaceutical applications. Int J Pharm. 2007;329(1–2):1–11.
   PubMed Web of Science ®Google Scholar
• Martín VI, Ostos FJ, Angulo M. Host-guest interactions between cyclodextrins and surfactants with functional groups at the end of the hydrophobic tail. J Colloid Interface Sci. 2017;491:336–348.
   PubMed Web of Science ®Google Scholar
• Szejtli J. Introduction and general overview of cyclodextrin chemistry. Chem Rev. 1998;98(5):1743–1754.
   PubMed Web of Science ®Google Scholar
• Kurkov SV, Loftsson T. Cyclodextrins. Int J Pharm. 2013;453:167–180.
   PubMed Web of Science ®Google Scholar
• Del Valle EMM. Cyclodextrins and their uses: a review. Process Biochem. 2004;39:1033–1046.
   Web of Science ®Google Scholar
• De Oliveira MG, Guimarães AG, Araújo AA, et al. Cyclodextrins: improving the therapeutic response of analgesic drugs: a patent review. Expert Opin Ther Pat. 2015;25(8):897–907.
   PubMed Web of Science ®Google Scholar
• Marques HMC. A review on cyclodextrin encapsulation of essential oils and volatiles. Flavour Fragr J. 2010;25:313–326.
   Web of Science ®Google Scholar
• Loftsson T, Jarho P, Másson M, et al. Cyclodextrins in drug delivery. Expert Opin Drug Deliv. 2005;2(2):335–351.
   PubMedGoogle Scholar
• Shishido TK, Jokela J, Kolehmainen CT, et al. Antifungal activity improved by coproduction of cyclodextrins and anabaenolysins in Cyanobacteria. Proc Natl Acad Sci U S A. 2015;112(44):13669–13674.
   PubMed Web of Science ®Google Scholar
• Cramer H, Anheyer D, Lauche R, et al. A systematic review of yoga for major depressive disorder. J Affect Disord. 2017;213:70–77.
   PubMed Web of Science ®Google Scholar
• Rubio JM, Markowitz JC, Alegria A, et al. Epidemiology of chronic and nonchronic major depressive disorder: results from the national epidemiologic survey on alcohol and related conditions. Depress Anxie. 2011;28:622–631.
   PubMed Web of Science ®Google Scholar
• Azar M, Pruessner M, Baer LH, et al. A study on negative and depressive symptom prevalence in individuals at ultra-high risk for psychosis. Early Interv Psychiatry. 2016. doi: 10.1111/eip.12386. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Herbert J, Lucassen PJ. Depression as a risk factor for Alzheimer’s disease: genes, steroids, cytokines and neurogenesis - what do we need to know? Front Neuroendocrinol. 2016;41:153–171.
   PubMed Web of Science ®Google Scholar
• Lai HM, Cleary M, Sitharthan T, et al. Prevalence of comorbid substance use, anxiety and mood disorders in epidemiological surveys, 1990–2014: a systematic review and meta-analysis. Drug Alcohol Depend. 2015;154:1–13.
   PubMed Web of Science ®Google Scholar
• Hallgren M, Stubbs B, Vancampfort D, et al. Treatment guidelines for depression: greater emphasis on physical activity is needed. Eur Psychiatry. 2017;40:1–3.
   PubMed Web of Science ®Google Scholar
• Bousman CA, Forbes M, Jayaram M, et al. Antidepressant prescribing in the precision medicine era: a prescriber’s primer on pharmacogenetic tools. BMC Psychiatry. 2017;17:60.
   PubMed Web of Science ®Google Scholar
• Papakostas GI. Managing partial response or nonresponse: switching, augmentation, and combination strategies for major depressive disorder. J Clin Psychiatry. 2009;70(Suppl 6):16–25.
   PubMed Web of Science ®Google Scholar
• Coppens E, Van Audenhove C, Iddi S, et al. Effectiveness of community facilitator training in improving knowledge, attitudes, and confidence in relation to depression and suicidal behavior: results of the OSPI-Europe intervention in four European countries. J Affect Disorders. 2014;165:142–150.
   PubMed Web of Science ®Google Scholar
• Pan T, Chu Y, Zhou M, et al. A high solubility anti-depression non-covalent compound, obtained by cladding beta-cyclodextrin and anti-depression compound SIPI5838 and SIPI5824. 2009;CN101259283A.
   Google Scholar
• Jiang A. Agomelatine clathrate useful for preparation of pharmaceutical composition for treatment of depression, comprises agomelatine and cyclodextrin. 2014;CN103623423A.
   Google Scholar
• Zhang X, Yuan Z, Wang Q. Clathrate of demethylated venlafaxine benzoate compound for preparing pharmaceuticals, contains specific cyclodextrin compound as inclusion material. 2013;CN103083293A.
   Google Scholar
• Szente L, Puskas I. Complex used for composition for pharmaceutical formulation e.g. film coated tablet, capsule, pellets and granules for regulating physiological and pathophysiological processes e.g. sleep, comprises agomelatine and cyclodextrin. 2014;WO2014012571A1.
   Google Scholar
• Ketner RJ. Composition used to taste mask unpleasant drugs in pharmaceutical applications comprises particles containing amorphous cyclodextrin in intimate contact with water soluble polymer. 2006;WO2006011044A1.
   Google Scholar
• Zhang H. Duloxetine hydrochloride spansules comprise duloxetine hydrochloride sustained-release pellets and 4 hour-release duloxetine hydrochloride pellets, prepared by e.g. mixing e.g. starch and dextrin, screening, and preparing pellets. 2012;CN102579403A.
   Google Scholar
• Rajewski RA, Mcginity JW, Mosher GL, et al. Controlled release, solid, pharmaceutical formulations comprise physical ixture of therapeutic agent, sulfoalkyl ether cyclodextrin(s) and release rate odifier(s). 2000;US6046177A.
   Google Scholar
• Li M, Wang L, Yang Y. Extracting antidepressant traditional Chinese medicine includes soaking radix curcumae and rhizoma cyperi with water, extracting volatile oil, and preparing volatile oil as beta-cyclodextrin inclusion. 2012;CN102451442A.
   Google Scholar
• Li X, Yan J. Medicinal composition useful for treating severe depression disorder comprises vortioxetine hydrobromide, betacyclodextrin,lactose, microcrystalline cellulose and magnesium stearate. 2015;CN104644635A.
   Google Scholar
• Gidwani SK, Singnurkar P, Tewari PK. New inclusion complex used as antidepressant, comprises bupropion hydrochloride and beta-cyclodextrin. 2002;11:US6462237B1.
   Google Scholar
• Jetti RR, Gorantla A, Beeravalli S, et al. Premix used to treat major depressive disorder, comprises amorphous vortioxetine hydrobromide and excipient comprising cyclodextrins, polyvinylpyrrolidone-vinyl acetate copolymers and/or microcrystalline cellulose. 2016;WO2016125190A2.
   Google Scholar
• Lv Q. Sertraline hydrochloride oral liquid comprises sertraline hydrochloride, mixture of stabilizer and solubilizer, thickener, preservative, aromatizer and solvent. 2010;CN101623252A.
   Google Scholar
• Ronsen B, Elrashidy R. Solid stabilized amorphous paroxetine composition. 1999;WO9916440A1.
   Google Scholar
• Mate S, Kapoor R, Huda I, et al. Taste masked pharmaceutical composition useful for the treatment of major depressive disorder, or anxiety disorder, comprises duloxetine optionally with at least one excipient. 2010;WO2010150219A1.
   Google Scholar
• Mosher G, Gayed AA, Wedel R, et al. Taste-masked aqueous liquid formulation for treating e.g. depression, anorexia, anxiety disorder, premature ejaculation, cancer, post myocardial infarction comprises sertraline, sulfoalkyl ether cyclodextrin with specific molar ration. 2005;WO2005117911A2.
   Google Scholar
• Mosher G, Gayed AA, Wedel R. Taste-masked aqueous oral liquid formulation useful for treatment of e.g. depression comprises sertraline, sulfoalkyl ether cyclodextrin and aqueous liquid carrier. 2005;US2005250738A1.
   Google Scholar
• Hu X, Huang C, Yang Y, et al. Inclusion complex, useful in a pharmaceutical composition for preparing antidepressant drugs, comprises supercritical extract of Magnolia officinalis and cyclodextrin. 2014;CN104107243–A.
   Google Scholar
• Geczy J. Pharmaceutical compositions containing propanamine derivatives and cyclodextrin. 1997;WO 1998042382A1.
   Google Scholar
• Guangzhi Y, Puchun F. Antidepressant composition containing citalopram and cyclodextrin. 2006;CN1839820.
   Google Scholar
• Mascagni P, Bottoni G. Complexes of paroxetine, with cyclodextrins or cyclodextrin derivatives. 2001;WO2001002393.
   Google Scholar
• Coutel-Egros A. The invention provides new inclusion compounds based on imipramine and cyclodextrin and pharmaceutical compositions which can be administered orally and are based on these new inclusion compounds. 1991;US5244881.
   Google Scholar
• Jiankang X, Mingdong X, Yaxiang C, et al. Novel method for preparing O-desvenlafaxine. 2007;CN101117320.
   Google Scholar
• Sanjay M, Ritesh K, Inderjeetsingh H, et al. Pharmaceutical composition of duloxetine. 2010;US20120164216.
   Google Scholar
• Caigu H, Huimin H. Preparation of non-crystal form edeplene oxalate and its co-precipitate. 2006;CN100999510.
   Google Scholar
• Santos RAS, Millán RDS, Passos JJ. Process for preparing inclusion compounds enclosing cyclodextrins and drugs, using a continuous-flow system. 2013;WO2013155586.
   Google Scholar
• Nikorasu EB. Drug composition for parenteral administration. 1990;JP H029825A.
   Google Scholar
• Wang L, Li M, Yang Y. Extraction process of anti-depression Chinese medicament. 2012;CN 102451442 A.
   Google Scholar
• James GM, Baldinger-Melich P, Philippe C, et al. Effects of selective serotonin reuptake inhibitors on interregional relation of serotonin transporter availability in major depression. Front Hum Neurosci. 2017;11:48.
   PubMed Web of Science ®Google Scholar
• Gryglewski G, Lanzenberger R, Kranz GS, et al. Meta-analysis of molecular imaging of serotonin transporters in major depression. J Cereb Blood Flow Metab. 2014;34:1096–1103.
   PubMed Web of Science ®Google Scholar
• Overstreet DH. Modeling depression in animal models. Methods Mol Biol. 2012;829:125–144.
   PubMedGoogle Scholar
• Di Cagno MP. The potential of cyclodextrins as novel active pharmaceutical ingredients: a short overview. Molecules (Basel, Switzerland). 2016;22:1.
   PubMed Web of Science ®Google Scholar
• Lima PS, Lucchese AM, Araujo-Filho HG, et al. Inclusion of terpenes in cyclodextrins: preparation, characterization and pharmacological approaches. Carbohy Polym. 2016;151:965–987.
   PubMed Web of Science ®Google Scholar
• Kellici TF, Liapakis G, Tzakos AG, et al. Pharmaceutical compositions for antihypertensive treatments: a patent review. Expert Opin Ther Pat. 2015;25:1305–1317.
   PubMed Web of Science ®Google Scholar
• Suvarna V, Gujar P, Murahari M. Complexation of phytochemicals with cyclodextrin derivatives – an insight. Biomed Pharmacother. 2017;88:1122–1144.
   PubMed Web of Science ®Google Scholar
• Stella VJ, He QC. Cyclodextrins. Toxicol Pathol. 2008;36:30–42.
   PubMed Web of Science ®Google Scholar
• Arima H, Hayashi Y, Higashi T, et al. Recent advances in cyclodextrin delivery techniques. Expert Opin Drug Deliv. 2015;12:1425–1441.
   PubMed Web of Science ®Google Scholar
• Jambhekar SS, Breen P. Cyclodextrins in pharmaceutical formulations II: solubilization, binding constant, and complexation efficiency. Drug Discov Today. 2016;21:363–368.
   PubMed Web of Science ®Google Scholar
• Jambhekar SS, Breen P. Cyclodextrins in pharmaceutical formulations I: structure and physicochemical properties, formation of complexes, and types of complex. Drug Discov Today. 2016;21:356–362.
   PubMed Web of Science ®Google Scholar
• Venturini CG, Nicolini J, Machado C, et al. Propriedades e aplicações recentes das ciclodextrinas. Quim Nova. 2008;31(2):360–368.
   Google Scholar
• Leclercq L. Interactions between cyclodextrins and cellular components: towards greener medical applications? Beilstein J Org Chem. 2016;12:2644–2662.
   PubMed Web of Science ®Google Scholar
• Ottinger EA, Kao ML, Carrillo-Carrasco N, et al. Collaborative development of 2-hydroxypropyl-beta-cyclodextrin for the treatment of Niemann-Pick type C1 disease. Curr Top Med Chem. 2014;14:330–339.
   PubMed Web of Science ®Google Scholar
• Loftsson T, Brewster ME. Pharmaceutical applications of cyclodextrins: basic science and product development. J Pharm Pharmacol. 2010;62:1607–1621.
   PubMed Web of Science ®Google Scholar
• Zhang M-Q, Rees DC. A review of recent applications of cyclodextrins for drug discovery. Expert Opin Ther Pat. 1999;9:1697–1717.
   Web of Science ®Google Scholar
• Sharma N, Baldi A. Exploring versatile applications of cyclodextrins: an overview. Drug Delivery. 2016;23:739–757.
   PubMed Web of Science ®Google Scholar
• Carrier RL, Miller LA, Ahmed I. The utility of cyclodextrins for enhancing oral bioavailability. J Control Rel. 2007;123:78–99.
   PubMed Web of Science ®Google Scholar
• Astray G, Gonzalez-Barreiro C, Mejuto JC, et al. A review on the use of cyclodextrins in foods. Food Hydrocolloids. 2009;23:1631–1640.
   Web of Science ®Google Scholar
• Passos JJ, De Sousa FB, Lula IS, et al. Multi-equilibrium system based on sertraline and β-cyclodextrin supramolecular complex in aqueous solution. Int J Pharm. 2011;421:24–33.
   PubMedGoogle Scholar
• Passos JJ, De Sousa FB, Mundim IM, et al. In vivo evaluation of the highly soluble oral β-cyclodextrin-sertraline supramolecular complexes. Int J Pharm. 2012;436:478–485.
   PubMedGoogle Scholar
• Géczy J, Bruhwyler J, Scuvée-Moreau J, et al. The inclusion of fluoxetine into γ-cyclodextrin increases its bioavailability: behavioural, electrophysiological and pharmacokinetic studies. Psychopharmacology. 2000;151:328–334.
   PubMed Web of Science ®Google Scholar
• Yoo SD, Yoon BM, Lee HS, et al. Increased bioavailability of clomipramine after sublingual administration in rats. J Pharm Sci. 1999;88(11):1119–1121.
   PubMed Web of Science ®Google Scholar
• Nakaoa Y, Horiguchi M, Nakamurad R, et al. LARETH-25 and b-CD improve central transitivity and central pharmacological effect of the GLP-2 peptide. Int J Pharm. 2016;515:37–45.
   PubMedGoogle Scholar